HUTCHMED (China) announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabin...
Belief BioMed announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Adminis...
Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, announced that ...
Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support&nb...
Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and...
Nelipak® Corporation (“Nelipak”), a leading global provider of healthcare packaging solutions, announced the opening of its new Asi...
Lonza Group AG, a world-leading contract development and manufacturing organisation (CDMO), has announced its decision to establish a new Global Capability...
The company also announced a strategic investment from Leonardo DiCaprio ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures an...
MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in the life sciences, announced the acqui...
Acadia Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the ...
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule ...
Meiji Seika Pharma Co., Ltd. announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodieste...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality...
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult...
© 2026 Biopharma Boardroom. All Rights Reserved.
